Dynavax Technologies
NEWS
Here’s a look at some of last week’s clinical trial announcements, including some from the American Society of Clinical Oncology Annual Meeting you might have missed.
Hundreds lose their jobs as companies close facilities and shift business focuses.
Dynavax plans to step away from immuno-oncology development and will lay off 37% of its staff as a result.
Asthma drug failed to show a statistically clinical improvement in controlling asthma, Dynavax said.
Dynavax announced it has secured a $175 million non-dilutive term loan agreement to commercialize Heplisav-B.
The FDA approved Dynavax’s Heplisav-B, it’s first new hepatitis B vaccine in the U.S. in more than 25 years.
Here’s a closer look at six drugs facing FDA decisions in November.
JOBS
IN THE PRESS